Incanthera’s strategy is to acquire, prepare and commercialise IP assets at the earliest opportunity in its development pathway, minimising traditional development model risk and investment required, whilst maximising the return of investment to shareholders.
This is achieved through the expertise within the team, it’s access to IP and its commercial and academic relationships.
This includes a 10 year pipeline deal with the ICT at Bradford University, securing first rights to any new oncology IP from the ICT.
The Company's current focus is a range of dermatological applications utilising its unique formulation and delivery technologies to meet currently unmet needs in the skincare market.
The Company is currently focussed upon delivering this range to a commercial partner.
The skincare market (including dermatology and cosmetics) is vast and growing rapidly, with global revenues projected to reach $180 billion by 2024.